praziquantel has been researched along with Body Weight in 24 studies
azinox: Russian drug
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Formulations that can be divided into four parts (to give 150 mg increments) are preferred for children weighing less than 11 kg; the same dosing can be applied with 600 mf praziquantel formulations that can be divided into four quarters or two halves from 11 kg body weight." | 7.79 | Practical dosing of praziquantel for schistosomiasis in preschool-aged children. ( Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013) |
| " Proper dosage adjustment of praziquantel by bodyweight can be difficult to achieve if accurate weighing scales are unavailable." | 5.39 | Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis. ( Belizario, VY; Chua, PL; Erfe, JM; Naig, JR, 2013) |
| "The cornerstone of schistosomiasis control is mass praziquantel treatment in high prevalence areas." | 3.80 | Dosing of praziquantel by height in sub-Saharan African adults. ( Brigham, T; Chasekwa, B; Humphrey, JH; Mbuya, MN; Palha De Sousa, CA; Prendergast, AJ; Tielsch, JM, 2014) |
| "Clinical schistosomiasis in endemic countries is treated with a single dose of praziquantel per 40 mg/kg body weight." | 3.80 | From a weighing scale to a pole: a comparison of two different dosage strategies in mass treatment of Schistosomiasis haematobium. ( Krantz, I; Mtweve, S; Nordin, P; Poggensee, G, 2014) |
| "Formulations that can be divided into four parts (to give 150 mg increments) are preferred for children weighing less than 11 kg; the same dosing can be applied with 600 mf praziquantel formulations that can be divided into four quarters or two halves from 11 kg body weight." | 3.79 | Practical dosing of praziquantel for schistosomiasis in preschool-aged children. ( Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013) |
| " For the majority of the patients, the drug was well tolerated and no serious adverse events were noted; however, clinical signs in the form of abdominal pain associated or not with diarrhea and vomiting were noted." | 2.78 | [Comparison of the efficacy and safety of praziquantel administered in single dose of 40 versus 60 mg/kg for treating urinary schistosomiasis in Mauritania]. ( Chitsulo, L; Konaté, L; Mamadou, D; Ouldabdallahi, M; Ouldbezeid, M; Ousmane, B, 2013) |
| " Praziquantel, dosed at 40 milligrams per kilogram bodyweight, is the drug of choice." | 1.43 | The Accuracy of Praziquantel Dose Poles for Mass Treatment of Schistosomiasis in School Girls in KwaZulu-Natal, South Africa. ( Aurlund, CG; Baan, M; Gagai, S; Galappaththi-Arachchige, HN; Kjetland, EF; Taylor, M; van Lieshout, L; Vennervald, BJ, 2016) |
| " Proper dosage adjustment of praziquantel by bodyweight can be difficult to achieve if accurate weighing scales are unavailable." | 1.39 | Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis. ( Belizario, VY; Chua, PL; Erfe, JM; Naig, JR, 2013) |
| "4) the pole estimated an acceptable dosage (30-60 mg/kg), a performance statistically similar to that observed in African populations." | 1.33 | The WHO dose pole for the administration of praziquantel is also accurate in non-African populations. ( Al-Awaidy, S; Allen, H; Assis, AM; Engels, D; Fenwick, A; Iwata, F; Kabatereine, NB; Montresor, A; Muth, S; Odermatt, P; Raja'a, YA; Savioli, L; Zulkifli, A, 2005) |
| "Schistosomiasis mansoni is a tropical helminthic disease characterized by parasite egg-induced granulomatous inflammation and cumulative fibrosis." | 1.32 | Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. ( Boros, DL; Gerard, HC; Hudson, AP; Singh, KP, 2004) |
| "), each time approximately 5 weeks after dosing with 60-80 OV metacercariae at weeks 0, 8, 16, 24 and 32." | 1.28 | Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic Praziquantel lacks carcinogenic potential. ( Ito, N; Moore, MA; Ruchirawat, S; Thamavit, W, 1992) |
| "Praziquantel 100 mg/kg was ineffective but 500 mg/kg significantly inhibited growth." | 1.27 | Echinococcus multilocularis: in vivo results of therapy with albendazole and praziquantel. ( Morris, DL; Reffin, D; Richards, KS; Taylor, DH, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elhenawy, AA | 1 |
| Ashour, RH | 1 |
| Nabih, N | 1 |
| Shalaby, NM | 1 |
| El-Karef, AA | 1 |
| Abou-El-Wafa, HS | 1 |
| Ouldabdallahi, M | 1 |
| Ousmane, B | 1 |
| Ouldbezeid, M | 1 |
| Mamadou, D | 1 |
| Konaté, L | 1 |
| Chitsulo, L | 2 |
| Strobel, H | 1 |
| de Ponte, M | 1 |
| Knoppe, TN | 1 |
| Bhushan, C | 1 |
| Olliaro, PL | 1 |
| Vaillant, M | 1 |
| Hayes, DJ | 1 |
| Montresor, A | 3 |
| Erfe, JM | 1 |
| Belizario, VY | 1 |
| Chua, PL | 1 |
| Naig, JR | 1 |
| Palha De Sousa, CA | 1 |
| Brigham, T | 1 |
| Chasekwa, B | 1 |
| Mbuya, MN | 1 |
| Tielsch, JM | 1 |
| Humphrey, JH | 1 |
| Prendergast, AJ | 1 |
| Nordin, P | 1 |
| Poggensee, G | 1 |
| Mtweve, S | 1 |
| Krantz, I | 1 |
| Baan, M | 1 |
| Galappaththi-Arachchige, HN | 1 |
| Gagai, S | 1 |
| Aurlund, CG | 1 |
| Vennervald, BJ | 1 |
| Taylor, M | 1 |
| van Lieshout, L | 1 |
| Kjetland, EF | 1 |
| Bonneau, S | 1 |
| Maynard, L | 1 |
| Tomczuk, K | 1 |
| Kok, D | 1 |
| Eun, HM | 1 |
| Singh, KP | 1 |
| Gerard, HC | 1 |
| Hudson, AP | 1 |
| Boros, DL | 1 |
| Odermatt, P | 1 |
| Muth, S | 1 |
| Iwata, F | 1 |
| Raja'a, YA | 1 |
| Assis, AM | 1 |
| Zulkifli, A | 1 |
| Kabatereine, NB | 1 |
| Fenwick, A | 1 |
| Al-Awaidy, S | 1 |
| Allen, H | 1 |
| Engels, D | 1 |
| Savioli, L | 1 |
| Strandgaard, H | 1 |
| Johansen, MV | 1 |
| Ørnbjerg, N | 1 |
| El-Banhawey, MA | 1 |
| Ashry, MA | 1 |
| El-Ansary, AK | 1 |
| Aly, SA | 1 |
| Idowu, ET | 1 |
| Mafe, MA | 1 |
| Appelt, B | 1 |
| Adewale, B | 1 |
| Adeneye, AK | 1 |
| Akinwale, OP | 1 |
| Manafa, OU | 1 |
| Akande, DO | 1 |
| Andrews, P | 1 |
| Dycka, J | 1 |
| Frank, G | 1 |
| Ahmed, SA | 1 |
| Gad, MZ | 1 |
| Badawy, AA | 1 |
| el-Badrawy, NM | 1 |
| Mansy, SS | 1 |
| Akl, MM | 1 |
| Abdel Hady, AM | 1 |
| Ebeid, FA | 1 |
| Hassan, MM | 1 |
| Adnyana, W | 1 |
| Ladds, PW | 1 |
| Blair, D | 1 |
| Thamavit, W | 3 |
| Moore, MA | 2 |
| Ruchirawat, S | 2 |
| Ito, N | 3 |
| Jack, A | 1 |
| Bradley, D | 1 |
| Shirai, T | 1 |
| Joong, KD | 1 |
| Hakoi, K | 1 |
| Pairojkul, C | 1 |
| Hoshiya, T | 1 |
| Hasegawa, R | 1 |
| Stephenson, LS | 1 |
| Latham, MC | 1 |
| Kurz, KM | 1 |
| Kinoti, SN | 1 |
| Taylor, DH | 1 |
| Morris, DL | 1 |
| Richards, KS | 1 |
| Reffin, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sanitation, Hygiene, Infant Nutrition Efficacy Project[NCT01824940] | 5,280 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Prevention of HIV and Improved Diagnosis of Adolescent Genital Disease in Bilharzia Endemic KwaZulu-Natal, South Africa[NCT01154907] | 6,500 participants (Anticipated) | Observational | 2010-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for praziquantel and Body Weight
| Article | Year |
|---|---|
[Comparison of the efficacy and safety of praziquantel administered in single dose of 40 versus 60 mg/kg for treating urinary schistosomiasis in Mauritania].
Topics: Adolescent; Anthelmintics; Body Weight; Child; Dose-Response Relationship, Drug; Drug-Related Side E | 2013 |
Comparison of three different treatment schedules for praziquantel (Cestocur®, Bayer) in the treatment of tapeworm infections (Moniezia spp.) and their impact on body weight gains in a German sheep flock.
Topics: Animals; Anthelmintics; Body Weight; Cestoda; Cestode Infections; Feces; Germany; Praziquantel; Shee | 2013 |
Anthelmintic efficacies of a tablet formula of ivermectin-praziquantel on horses experimentally infected with three Strongylus species.
Topics: Animals; Anthelmintics; Arteries; Body Weight; Double-Blind Method; Female; Horse Diseases; Horses; | 2009 |
Single dose metrifonate or praziquantel treatment in Kenyan children. II. Effects on growth in relation to Schistosoma haematobium and hookworm egg counts.
Topics: Adolescent; Body Height; Body Weight; Child; Female; Hookworm Infections; Humans; Kenya; Male; Paras | 1989 |
20 other studies available for praziquantel and Body Weight
| Article | Year |
|---|---|
Insulin growth factor inhibitor as a potential new anti-schistosoma drug: An in vivo experimental study.
Topics: Animals; Antigens, Helminth; Body Weight; Female; Glucose Transporter Type 4; Homeostasis; Insulin R | 2017 |
Practical dosing of praziquantel for schistosomiasis in preschool-aged children.
Topics: Africa South of the Sahara; Anthelmintics; Body Weight; Brazil; Child; Child, Preschool; Dose-Respon | 2013 |
Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis.
Topics: Body Height; Body Weight; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Adm | 2013 |
Dosing of praziquantel by height in sub-Saharan African adults.
Topics: Adolescent; Adult; Anthelmintics; Body Height; Body Weight; Female; Humans; Male; Middle Aged; Prazi | 2014 |
From a weighing scale to a pole: a comparison of two different dosage strategies in mass treatment of Schistosomiasis haematobium.
Topics: Adolescent; Body Height; Body Weight; Child; Drug Dosage Calculations; Female; Humans; Male; Neglect | 2014 |
The Accuracy of Praziquantel Dose Poles for Mass Treatment of Schistosomiasis in School Girls in KwaZulu-Natal, South Africa.
Topics: Adolescent; Body Height; Body Mass Index; Body Weight; Child; Cohort Studies; Cross-Sectional Studie | 2016 |
Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice.
Topics: Animals; Anthelmintics; Body Weight; Cell Count; Cells, Cultured; Collagen; Cytokines; Female; Gene | 2004 |
The WHO dose pole for the administration of praziquantel is also accurate in non-African populations.
Topics: Adolescent; Adult; Anthelmintics; Body Height; Body Weight; Child; Child, Preschool; Drug Administra | 2005 |
Field testing of the WHO dose pole for administration of praziquantel in the treatment of opisthorchiasis in Lao PDR.
Topics: Adolescent; Adult; Aged; Anthelmintics; Body Height; Body Weight; Child; Dose-Response Relationship, | 2007 |
Effect of Curcuma longa or parziquantel on Schistosoma mansoni infected mice liver--histological and histochemical study.
Topics: Alkaline Phosphatase; Animals; Body Weight; Curcuma; Liver Diseases; Male; Mice; Organ Size; Phytoth | 2007 |
Height as a substitute for weight for estimating praziquantel dosage.
Topics: Adolescent; Adult; Anthelmintics; Body Height; Body Weight; Child; Child, Preschool; Dose-Response R | 2007 |
Effect of praziquantel on clinical-chemical parameters in healthy and schistosome-infected mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Blood Cell Count; | 1980 |
Effect of schistosomal infection and its treatment on some key enzymes of glucose metabolism in mice livers.
Topics: Animals; Body Weight; Citric Acid Cycle; Female; Glucose; Glycolysis; Liver; Liver Glycogen; Male; M | 1995 |
Evaluation of colchicine with or without praziquantel therapy in the control of hepatic fibrosis in murine schistosomiasis.
Topics: Animals; Body Weight; Colchicine; Collagen; Connective Tissue; Female; Liver Cirrhosis, Experimental | 1996 |
Efficacy of praziquantel in the treatment of green sea turtles with spontaneous infection of cardiovascular flukes.
Topics: Administration, Oral; Alanine Transaminase; Animals; Antiplatyhelmintic Agents; Aspartate Aminotrans | 1997 |
Lack of modulation effects of praziquantel on DMN-induced lesion development in the Syrian hamster liver.
Topics: Animals; Body Weight; Carcinoma, Hepatocellular; Cricetinae; Dimethylnitrosamine; Drug Interactions; | 1992 |
Scales modified for dose determination in population-based chemotherapy.
Topics: Adult; Body Weight; Child, Preschool; Community Health Workers; Drug Administration Schedule; Evalua | 1991 |
Promotion of rat hepatocarcinogenesis by praziquantel.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Carcinogens; Diethylnitrosa | 1991 |
Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic Praziquantel lacks carcinogenic potential.
Topics: Animals; Body Weight; Cricetinae; Liver Diseases, Parasitic; Liver Neoplasms, Experimental; Male; Me | 1992 |
Echinococcus multilocularis: in vivo results of therapy with albendazole and praziquantel.
Topics: Albendazole; Animals; Anthelmintics; Arvicolinae; Benzimidazoles; Body Weight; Echinococcosis; Echin | 1988 |